Reply
We are grateful for the interest shown in our training.
After the appraisal of the first course, we did reduce the course to a 2-day one, as is stated in the discussion on page 21. Funding for locums was from the local Health Action Zone, although finding locums was a problem for the pharmacists concerned.
The main point to note is that the first course was held in early 2000, when the idea of pharmacists doing this work was very new (we were only the second project in the UK to go live) and when over-the-counter sale had not yet been approved. Public and professional reaction was untested, and a great deal of time was spent helping the pharmacists to feel confident if challenged about their right to supply emergency hormonal contraception. The wisdom of this was shown when the Daily Mail published an inaccurate story, as detailed in the paper; the pharmacists concerned had an extremely unpleasant experience but coped amazingly well. We were also anxious that the participants should see themselves as part of a seamless service including all sexual health providers, and had no idea of what demand might be (it has in fact reached 10 000 supplies a year across our very deprived inner city area).
Perhaps the moral of this is that today's daring innovation is tomorrow's boring received wisdom, as every department that has set up nurses supplying to a Patient Group Direction will recognise!
Ectopic pregnancy following use of progestin-only ECPs

Madam
We read with great interest the editorial about ectopic pregnancy (EP) following use of progestin-only emergency contraceptive pills (ECPs). 1 The authors note that 12 EPs in women who used levonorgestrel ECPs have been reported in the UK and that a handful of additional cases have been reported in other countries. As the authors acknowledge, this information cannot be used to calculate the probability that a pregnancy occurring after use of the treatment will be ectopic because the total number of pregnancies needed for the denominator of the calculation is unknown. Nevertheless, based on these case reports, Britain's Committee on Safety of Medicines (CSM) has advised that if a woman who has used progestin-only ECPs becomes pregnant, "the possibility of an ectopic pregnancy should be considered". 2 Data from clinical trials of ECPs can yield an accurate estimate of the rate of EP because pregnancies in these trials are systematically documented and thus provide a valid denominator for the rate. Through a search of the published literature, we identified five clinical trials of levonorgestrel-only ECPs. [3] [4] [5] [6] [7] As shown in Table 1 , these trials reported a total of 97 intrauterine pregnancies and one EP. The proportion of pregnancies that were ectopic was thus 1.02% (95% exact CI 0.02%-5.55%).
This proportion is consistent with the reported national rate of 12.4 and 19.7 per 1000 pregnancies in England and Wales and in the USA, respectively. 8, 9 Therefore, these trials provide no evidence to suggest that progestinonly ECPs increase the chance that a pregnancy will be ectopic. Moreover, because ECPs are so effective at preventing pregnancy in general, they certainly reduce a woman's absolute risk of EP.
We agree with the authors of the Editorial and with the CSM that a woman who has used progestin-only ECPs and who subsequently has clinical symptoms of EP should seek appropriate evaluation, as should any woman with such symptoms. However, no evidence exists to warrant heightened concern in users of progestinonly ECPs. 
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